Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

61.55 -0.06 (-0.10%)
Official Closing Price Updated: 7:00 PM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
95 96 Next >
News headline image
Bristol Myers Squibb’s Cancer Drug Just Doubled Survival Time Without Progression — Here’s Why It Matters ↗
The medication, which is being developed with the company's Chinese partner, did very well in a late-stage clinical trial. 
Via The Motley Fool
News headline image
3 Cheap Dividend Stocks I'd Buy Without Any Hesitation ↗
Don't overthink it. These are blue chip stocks that have simply gone on sale and would be solid additions to almost any income portfolio. 
Via The Motley Fool
News headline image
Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock ↗
Bristol-Myers Squibb's iza-bren cut breast cancer progression risk by up to 38% in a Phase 3 trial, lifting shares and raising implications for rivals like Exelixis. 
Via MarketBeat
Topics Intellectual Property
Bristol-Myers Squibb (NYSE:BMY): Weighing Dividend Quality for Income Investors ↗
Via Chartmill
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Bristol Myers Squibb: Bargain Buy or Value Trap? ↗
The healthcare stock trades at a forward earnings multiple of just nine, and its growth rate has been in the low single digits this year. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 High-Yield Stocks to Buy With $1,000 Right Now ↗
These stocks pay yields far above the S&P 500's. And they keep raising their dividends. 
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study
From Bristol Myers Squibb
Via Business Wire
News headline image
Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings? ↗
Bristol Myers Squibb is facing a sizable patent cliff, but that's not unusual in the pharma sector. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions
From Pathos AI
Via Business Wire
News headline image
Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study
From Bristol Myers Squibb
Via Business Wire
News headline image
Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb? ↗
One of these pharma stocks offers more income, but the other offers a safer dividend. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue ↗
Pfizer's revenue swung sharply lower before stabilizing, while Bristol Myers Squibb kept climbing steadily—a divergence that matters for long-term investors. 
Via The Motley Fool
News headline image
Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility ↗
Bristol Myers Squibb has led in seven of eight quarters, but Novo Nordisk's recent spike signals a shift worth watching for income-focused investors. 
Via The Motley Fool
News headline image
Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results? ↗
Eli Lilly's revenue nearly doubled over two years while Bristol Myers Squibb remained relatively flat, widening the gap between these two pharma giants. 
Via The Motley Fool
Topics Artificial Intelligence Lawsuit
News headline image
AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue? ↗
AbbVie's revenue lead has widened to $4 billion per quarter, but Bristol Myers shows surprising resilience despite slower growth. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? ↗
Amgen boasts stronger revenue growth, while Bristol Myers Squibb generates nearly 60% more free cash flow at half the valuation. 
Via The Motley Fool
S&P 500 Top Movers: Gainers and Losers From Today's US Session ↗
Via Chartmill
Topics Stocks
News headline image
Have $1,000 to Invest? This Dirt Cheap Pharma Stock Pays You 4.2% to Wait. ↗
Consider this pharma company's turnaround, not its dividend, its main appeal. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Unpopular Stocks We Keep Off Our Radar
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord... 
Via StockStory
News headline image
Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? ↗
It has been a volatile year for the biotech. 
Via The Motley Fool
News headline image
Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? ↗
Bristol-Myers trades at a significant valuation discount, but its higher leverage and patent risks contrast sharply with Johnson & Johnson's diversified stability. 
Via The Motley Fool
Topics Intellectual Property
These S&P500 stocks are gapping in today's session ↗
Via Chartmill
Top S&P500 movers in Wednesday's session ↗
Via Chartmill
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
Q2 Earnings Outperformers: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? ↗
Bristol Myers Squibb recovered to $7.1B in net income while Eli Lilly more than doubled profits to $20.6B, a stark contrast in momentum that reshapes the value-versus-growth debate. 
Via The Motley Fool
News headline image
Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
95 96 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.